Please try another search
Telix Pharmaceuticals Limited, a commercial-stage biopharmaceutical company, focuses on the development and commercialization of diagnostic and therapeutic radiopharmaceuticals and related medical devices for cancer and rare diseases in Australia, Belgium, Japan, Switzerland, and the United States. Its products portfolio include Illuccix for the treatment of prostate cancer;, TLX591, a radio antibody-drug conjugate, which is in phase 3 clinical trial for the treatment of prostate cancer; TLX250-CDx that is in Phase III clinical trials for the treatment and diagnosis of renal (kidney) cancer; TLX101-CDx for the diagnosis and treatment of glioblastoma (brain cancer); TLX66-CDx to treat bone marrow conditioning and rare diseases; TLX300-CDx for the treatment and diagnosis of soft tissue sarcoma; TLX250, which is in Phase II clinical trials for the diagnosis and treatment of kidney cancer; TLX101 that is in Phase II clinical trials for the treatment of glioblastoma (brain cancer); TLX66, which is in Phase II clinical trials for the treatment of bone marrow conditioning and rare diseases; and TLX300 that is in Phase I clinical trial for the treatment and diagnosis of soft tissue sarcoma. The company also develops TLX592, a prostate cancer therapy candidate for targeted alpha therapy; and TLX599-CDx for treatment of prostate cancer imaging agent. The company was founded in 2015 and is headquartered in North Melbourne, Australia.
Name | Age | Since | Title |
---|---|---|---|
Klaus Kopka | - | - | Member of the Scientific Advisory Board |
Rodney W. Hicks | - | - | Member of the Scientific Advisory Board |
Tiffany P. Olson | 65 | 2022 | Independent Non-Executive Director |
Andreas Kluge | 59 | 2017 | Chief Medical Advisor & Non-Executive Director |
Jean-François Chatal | - | - | Member of the Scientific Advisory Board |
Jann Elizabeth Skinner | 66 | 2018 | Independent Non-Executive Director |
Jason Lewis | - | - | Member of the Scientific Advisory Board |
Mark Alexander Nelson | 64 | 2017 | Independent Non-Executive Director |
Chaitanya R. Divgi | - | - | Member of the Scientific Advisory Board |
Frederik L. Giesel | - | 2020 | Member of Scientific Advisory Board |
Christian P. Behrenbruch | 48 | 2017 | Co-Founder, MD, Group CEO & Executive Director |
Richard Baum | - | - | Member of the Scientific Advisory Board |
Stefano Fanti | - | 2019 | Scientific Advisor |
Neil H. Bander | - | - | Member of the Scientific Advisory Board |
Richard Zimmermann | - | 2017 | Member of Scientific Advisory Board |
Harry Kevin McCann | 83 | 2017 | Independent Non-Executive Chairman |
Samuel Samnick | - | - | Member of the Scientific Advisory Board |
Are you sure you want to block %USER_NAME%?
By doing so, you and %USER_NAME% will not be able to see any of each other's Investing.com's posts.
%USER_NAME% was successfully added to your Block List
Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.
I feel that this comment is:
Thank You!
Your report has been sent to our moderators for review